HS-10502 Combination Treatment in Patients With Advanced Solid Tumors

NCT06769425 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

157

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Ovarian Cancer
HER2-negative
Advanced Breast Cancer
TNBC
Advanced Prostate Cancer
Advanced Gastric Cancer

Interventions

DRUG: HS-10502 + NHA
DRUG: HS-10502 + HS-20093
DRUG: HS-10502+ Apatinib
DRUG: HS-10502 + HS-20089
DRUG: HS-10502 + Platinum + Bevacizumab
DRUG: HS-10502 + nab-paclitaxel or Docetaxel or Irinotecan
DRUG: HS-10502 + Bevacizumab

Sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd.